We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chromosome Buffers Improve Understanding of Melanoma

By LabMedica International staff writers
Posted on 01 Oct 2014
Buffers that guard against damage to the ends of chromosomes could hold the key to a better understanding of malignant melanoma, the deadliest form of skin cancer.

The ends of chromosomes are protected from instability by tandem nucleotide repeats, known as telomeres and these telomeres shorten both with age and following exposures associated with cancer risk, such as smoking and ultraviolet (UV) irradiation.

An international team of scientists led by those at the University of Leeds (UK) investigated variants identified by the telomere meta-analysis in a genome-wide association study (GWAS) of melanoma. More...
The study consisted of 11,108 case patients and 13,933 control patients from Europe, Israel, the USA, and Australia. The scientists concentrated on seven single nucleotide polymorphisms (SNPs) from the telomere meta-analysis.

In phase 1, samples were genotyped on the HumanHap300 BeadChip version 2 duo array with 317k tagging SNPs (Illumina; San Diego, CA, USA) and in France, cases were genotyped on the Illumina HumanCNV370k array. The phase 2 samples were genotyped on the Illumina 610k array.

The team created a score representing genetically-determined telomere length based on all the established telomere associated genes and found that this score was associated with melanoma risk. The one in four people predicted to have the longest telomeres are at 30% increased risk of developing melanoma compared to those one in four predicted to have the shortest telomeres.

Mark M. Iles, PhD, the led author of the study said, “For the first time, we have established that the genes controlling the length of these telomeres play a part in the risk of developing melanoma. More studies are needed to better understand the relationship between melanoma and telomeres, but learning more about how an individual's genetic telomere profile influences their risk developing melanoma may help us. It will improve our understanding of melanoma biology and gives us a target towards developing potential treatments as well as potentially helping shape advice on what behavioral changes people might make.” The study was published in the October 2014 issue of the Journal of the National Cancer Institute.

Related Links:
.
University of Leeds 
Illumina 



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.